Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis.
Burger
David M
DM
Magis-Escurra
Cecile
C
van den Berk
Guido El
GE
Gelinck
Luc B S
LB
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000378:metabolism*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage; D015498:HIV-2 / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000068898:Raltegravir Potassium; D012293:Rifampin / Q000008:administration & dosage; D014376:Tuberculosis / Q000188:drug therapy* / Q000276:immunology
D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D012293:Rifampin